Rasino Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.46 Cr
- Satisfied Charges ₹ 3.00 Cr
- Revenue Growth 59.94%
- Profit Growth -416.11%
- Ebitda -67.32%
- Net Worth -8.94%
- Total Assets 8.10%
About Rasino Drugs
Rasino Drugs Private Limited (RDPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 November 2015 (Nine years and two months 6 days old ). Its registered office is in Ambernath, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹5.46 Cr. The company has closed loans amounting to ₹3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Swarada Doshi and Paresh Doshi serve as directors at the Company.
Company Details
- Location
Ambernath, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24233MH2015PTC270493
- Company No.
270493
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Nov 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Rasino Drugs Private Limited offer?
Rasino Drugs Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Organic Compounds, Chemical Compound, Chemical Raw Material, Pharma Ingredients & Raw Materials, Anti Infective API, Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Miconazole Nitrate API, API Intermediate.
Who are the key members and board of directors at Rasino Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swarada Doshi  | Director | 26-Nov-2015 | Current |
| Paresh Doshi | Director | 26-Nov-2015 | Current |
Financial Performance of Rasino Drugs.
Rasino Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 59.94% increase. The company also saw a substantial fall in profitability, with a 416.11% decrease in profit. The company's net worth dipped by a decrease of 8.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rasino Drugs?
In 2023, Rasino Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rasino Herbs Private LimitedSwarada Doshi and Paresh Doshi are mutual person
Charges (Loans)
₹54.58 M
₹29.98 M
Charges Breakdown by Lending Institutions
- Others : 5.46 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jan 2024 | Others | ₹5.46 Cr | Open |
| 22 Apr 2022 | Axis Bank Limited | ₹2.58 M | Satisfied |
| 20 Aug 2018 | Axis Bank Limited | ₹2.74 Cr | Satisfied |
How Many Employees Work at Rasino Drugs?
Rasino Drugs has a workforce of 19 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rasino Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rasino Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
